The latest update is out from Gain Therapeutics (GANX).
Gain Therapeutics, Inc. has successfully completed the multiple ascending dose phase of its pioneering Phase 1 study for GT-02287, a promising new treatment for Parkinson’s Disease, with no serious adverse events or discontinuations reported. This milestone, announced on July 9, 2024, represents a key advancement in the development of novel therapies for neurological conditions, potentially signaling hope for patients and investors alike.
See more insights into GANX stock on TipRanks’ Stock Analysis page.
